MedTrace Logo

Neovascular Morphology and Persistent Disease Activity Among Patients With NV AMD

NCT02367365 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2018-02-12

No results posted yet for this study

Summary

Neovascular Age-Related Macular Degeneration (NV AMD) remains the leading cause of vision loss among people over 65. Intravitreal injections with drugs that block VEGF have revolutionized treatment of NV AMD. However, less than 40% of treated patients have clinically significant imporovement in vision. In this study, we will determine the relative frequency of neovascular subtypes in two groups: 1) a representative, treatment-naive NV AMD patient population, and 2) a population of patients who develop recurrent NV AMD activity while off treatment and assess the frequency of persistent disease activity (PDA) according to specific neovascular morphologic subtypes. This information will clarify the scope of the PDA problem and will identify patients with PDA who may benefit from additional therpeutic strategies.

Conditions

  • Neovascular Age-Related Macular Degeneration

Interventions

OTHER

No Intervention

No intervention

OTHER

No Intervention

No intervention

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    collaborator INDUSTRY

  • Duke University

    lead OTHER

Principal Investigators

  • Scott Cousins, MD · Duke University

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02367365 on ClinicalTrials.gov